Issue 1, 2019

A Viedma ripening route to an enantiopure building block for Levetiracetam and Brivaracetam

Abstract

A simple route to enantiomerically pure (S)-2-aminobutyramide – the chiral component of the anti-epileptic drugs Levetiracetam and Brivaracetam has been developed. This approach is based on the rational design and application of a Viedma ripening process. The practical potential of the process is demonstrated on a large scale.

Graphical abstract: A Viedma ripening route to an enantiopure building block for Levetiracetam and Brivaracetam

Supplementary files

Article information

Article type
Communication
Submitted
26 oct. 2018
Accepted
05 nov. 2018
First published
05 nov. 2018

Org. Biomol. Chem., 2019,17, 35-38

A Viedma ripening route to an enantiopure building block for Levetiracetam and Brivaracetam

I. Baglai, M. Leeman, R. M. Kellogg and W. L. Noorduin, Org. Biomol. Chem., 2019, 17, 35 DOI: 10.1039/C8OB02660B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements